Immune Therapy For Relapsed Or Refractory Diffuse Large B Cell Lymphomas

Given the poor prognosis of patients with relapsed or refractory diffuse large B-cell lymphomas (R/R LDGCB), the development of novel alternative strategies is necessary. In these highly chemoresistant diseases, antitumoral responses may be obtained by enabling the immune system to kill malignant cells in an indirect manner. The last decade has witnessed the emergence of novel forms of immunotherapy, including immunoconjugates, immunomodulatory drugs (IMiDS), immune checkpoint blockers, bispecific antibodies and chimeric antigen receptor T cells (CAR-T cells). These treatments have shown phenomenal successes, sometimes curative, compared to the results obtained with conventional approaches. These immunotherapies will likely transform the treatment paradigms for R/R LDGCB and that their earlier use in the therapeutic strategy may be addressed in patients at high-risk of chemoresistance.